In recent years, many observational studies [11–16] and some meta-analyses [17] have reported that lower plasma adiponectin levels are significantly associated with the presence and severity of NAFLD, especially in patients without T2DM, thereby suggesting that hypoadiponectinemia might represent a risk factor for NAFLD. This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatotic liver disease.